Dr Rebecca Kristeleit is a Clinical Senior Lecturer and Consultant Medical Oncologist at UCL/UCLH. She specialises in the treatment of gynaecological cancers such as cervical cancer, endometrial cancer, and ovarian cancer. She also has a specialist interest in drug development as well and is leading several clinical trials of novel agents relevant to gynaecological malignancies including PARP inhibitors.
Dr Kristeleit qualified in medicine from St Andrew’s and Manchester Universities including eight months at the University of Lausanne (Switzerland) on an Erasmus scholarship. Following general medical training in London, she undertook my medical oncology training at The Royal Marsden Hospital and a CRUK-funded research fellowship at the Institute of Cancer Research. Subsequently, Dr Kristeleit spent a year as a senior research fellow on the Drug Development Unit at the Royal Marsden Hospital gaining specialist experience in the design and conduct of early phase clinical trials and translational medicine.
Dr Kristeleit's research work, as part of the UCLH gynaecological oncology team, Clinical Research Facility at UCLH and the UCL Cancer Institute, is focused on the development of early-phase clinical trials and translational research to identify and evaluate innovative treatment strategies for gynaecological malignancies as well as other solid tumours.